At HIMSS14, Microsoft Corp. showcased a range of health organizations, including Epic and AirStrip, that have improved care team collaboration and productivity, expanded mobility and enhanced patient care through Windows 8.1 devices and apps, and Windows Embedded solutions. With the Windows 8.1 platform of clinical-grade devices, apps and services, including Microsoft Surface, mobile care teams can: communicate with each other via a variety of methods; gain access to full-function EMRs from anywhere at any time; and use U.S. Food and Drug Administration (FDA) -cleared clinician apps to deliver mobile-based care and guidance.


Noninvasive imaging of carotid artery plaque with magnetic resonance imaging (MRI) can accurately predict future cardiovascular events like strokes and heart attacks in people without a history of cardiovascular disease, according to a study published online in the journal Radiology.


March 5, 2014 — Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery have developed a unique, compact and relatively inexpensive imaging device to “light up” malignant brain tumors and other cancers.


March 5, 2014 — vRad (Virtual Radiologic), the largest telemedicine company and radiology practice in the United States, announced its newest set of indices, the “Day in the Life of Radiology,” part of the RPC (Radiology Patient Care) Indices available for free and unrestricted use at vRad’s website.

March 5, 2014 — Esaote has launched CrystaLine, a significant evolution of its ultrasound technology that delivers new levels of accuracy, quality, versatility and value. Esaote will showcase the new technology at the 2014 annual meeting of the European Congress of Radiology in Vienna, March 6-10.

March 5, 2014 — Claron Technology announced it has been awarded CE mark for its NilRead zero-footprint viewer for the diagnostic interpretation of medical images. Coinciding with this, Claron has opened its European headquarters in Hasselt, Belgium, under the direction of Tom Tilmans, director of sales. In addition to spearheading direct sales efforts, Tilmans will recruit and manage a team of European partners and distributors.

March 4, 2014 — Advanced Accelerator Applications (AAA), a growing international player in molecular nuclear medicine, announced they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 Dotatate.

Subscribe Now